The US Food and Drug Administration has approved the first injectable treatment to prevent HIV, marking a pivotal moment in the fight against the epidemic.
GlaxoSmithKline said late on Monday that US drug regulators had approved use of Apretude, a long-acting injectable drug made by ViiV Healthcare, which is majority owned by GSK and also backed by Pfizer and Shionogi.
The drug, cabotegravir, can be given as few as six times a year, in contrast with the current regimen for pre-exposure prophylaxis (PrEP), which requires adherence to a daily pill.
您已閱讀25%（551字），剩餘75%（1690字）包含更多重要資訊，訂閱以繼續探索完整內容，並享受更多專屬服務。